Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 8/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.37 |
| ▸ | YTHDC1 | Q96MU7 | 2/20 | 0.35 |
| ▸ | PI4KA | P42356 | 6/20 | 0.34 |
| ▸ | PI4K2B | Q8TCG2 | 6/20 | 0.34 |
| ▸ | PI4K2A | Q9BTU6 | 6/20 | 0.34 |
| ▸ | PI4KB | Q9UBF8 | 6/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL441875 | 0.77 | ADORA1 (0.62) | ADORA2AADORA1YTHDC1PI4KAPI4K2B | |
| SCHEMBL9074153 | 0.75 | ADORA2A (0.60) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL320849 | 0.75 | ADORA2A (0.41) | ADORA2AADORA1YTHDC1PI4KAPI4K2B | |
| SCHEMBL784393 | 0.72 | ADORA2A (0.66) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL14356547 | 0.72 | PI4KA (0.66) | ADORA2AADORA1YTHDC1PI4KAPI4K2B | |
| SCHEMBL24236911 | 0.72 | YTHDC1 (0.41) | ADORA2AADORA1YTHDC1PI4KAPI4K2B | |
| SCHEMBL14190719 | 0.72 | ADORA2A (0.66) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL1898082 | 0.71 | HSP90AB1 (0.41) | — | |
| SCHEMBL27597435 | 0.71 | ADORA2A (0.34) | ADORA2AADORA1YTHDC1PI4KAPI4K2B | |
| SCHEMBL13811638 | 0.71 | SRC (0.47) | ADORA2AADORA1YTHDC1PI4KAPI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 259 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117092260-A | Liquid chromatography-mass spectrometry analysis method for simultaneously detecting 6 immunosuppressant concentrations | 苏州和合医学检验有限公司 | 2023-11-21 | — | — | CN | claimed |
| CN-117074581-A | Pretreatment method for blood sample for simultaneously detecting 6 immunosuppressant concentrations | 苏州和合医学检验有限公司 | 2023-11-17 | — | — | CN | claimed |
| CN-117074582-A | Method for simultaneously detecting concentration of 6 immunosuppressants in blood | 苏州和合医学检验有限公司 | 2023-11-17 | — | — | CN | claimed |
| CN-101856313-B | Association of monosaccharides and adenosine and its cosmetic use | OREAL | 2014-02-19 | — | — | CN | claimed |
| CN-101856313-A | Association of monosaccharides and adenosine and its cosmetic use | OREAL | 2010-10-13 | — | — | CN | claimed |
| US-20100029692-A1 | METHODS OF OPTIMIZING DRUG THERAPEUTIC EFFICACY FOR TREATMENT OF IMMUNE-MEDIATED GASTROINTESTINAL DISORDERS | HOPITAL-SAINTE-JUSTINE (CA) | 2010-02-04 | — | — | US | claimed |
| EP-1825254-A4 | METHOD FOR OPTIMIZING THIOPURINE EFFICACY AND TOXICITY USING MASS SPECTROMETRY | PROMETHEUS LAB INC (US) | 2009-01-14 | — | — | EP | claimed |
| US-7326694-B2 | Methods of optimizing drug therapeutic efficacy for treatment of immune-mediated gastrointestinal disorders | HOPITAL SAINTE-JUSTINE (CA) | 2008-02-05 | — | — | US | claimed |
| EP-1825254-A2 | METHOD FOR OPTIMIZING THIOPURINE EFFICACY AND TOXICITY USING MASS SPECTROMETRY | Prometheus Laboratories, Inc. (US) | 2007-08-29 | — | — | EP | claimed |
| US-20070197554-A1 | METHODS OF OPTIMIZING DRUG THERAPEUTIC EFFICACY FOR TREATMENT OF IMMUNE-MEDIATED GASTROINTESTINAL DISORDERS | HOPITAL SAINTE-JUSTINE (CA) | 2007-08-23 | — | — | US | claimed |
| US-20040097527-A1 | Methods of optimizing drug therapeutic efficacy for treatment of immune-mediated gastrointestinal disorders | HOPITAL SAINTE-JUSTINE | 2004-05-20 | — | — | US | claimed |
| US-6680302-B2 | ADMINISTERING A 6- MERCAPTOPURINE DRUG TO A PATIENT HAVING IMMUNE-MEDIATED GASTROINTESTINAL DISORDER AND DETERMINING A LEVEL OF 6-THIOGUANINE IN THE PATIENT | HOSPITAL SAINTE-JUSTINE (CA) | 2004-01-20 | — | — | US | claimed |
| CN-1431909-A | Combinations for treating neoplasms | YU BAOFA (US) | 2003-07-23 | — | — | CN | claimed |
| US-20020082239-A1 | Methods of optimizing drug therapeutic efficacy for treatment of immune-mediated gastrointestinal disorders | HOPITAL-SAINTE-JUSTINE (CA) | 2002-06-27 | — | — | US | claimed |
| US-6355623-B2 | DETERMINING THE LEVEL OF 6-THIOGUANINE METABOLITE WHEREIN A LEVEL OF 6-THIOGUANINE LESS THAN ABOUT 230 PMOL PER 8 X 108 RED BLOOD CELLS INDICATES A DRUG INCREASE; A LEVEL OF 400PMOL INDICATES A DECREASE; NONTOXIC | HOPITAL-SAINTE-JUSTINE (CA) | 2002-03-12 | — | — | US | claimed |
| EP-1115403-A1 | OPTIMIZED USE OF 6-MERCAPTOPURINE DRUG IN THE TREATMENT OF IMMUNE-MEDIATED GASTROINTESTINAL DISORDERS | Hospital Sainte-Justine (CA) | 2001-07-18 | — | — | EP | claimed |
| US-20010006970-A1 | Determining the level of 6-thioguanine metabolite wherein a level of 6-thioguanine less than about 230 pmol per 8 x 108 red blood cells indicates a drug increase; a level of 400pmol indicates a decrease; nontoxic | HOPITAL SAINTE-JUSTINE | 2001-07-05 | — | — | US | claimed |
| WO-2000016780-A1 | OPTIMIZED USE OF 6-MERCAPTOPURINE DRUG IN THE TREATMENT OF IMMUNE-MEDIATED GASTROINTESTINAL DISORDERS | HOPITAL SAINTE-JUSTINE (CA) | 2000-03-30 | — | — | WO | claimed |
| CN-1220605-A | Nucleotide analogues for topical treatment of skin cell proliferative disorders | KARL Y HOSTETLER (US) | 1999-06-23 | — | — | CN | claimed |
| US-5264561-A | Reaction with an acid anhydride in the presence of a catalyst such as zirconium oxide, titanium oxide, alumina and acetic anhydride | JAPAN TOBACCO INC. (JP) | 1993-11-23 | — | — | US | claimed |